in Sweet's syndrome and pyoderma gangrenosum, however, in
subcorneal pustular dermatosis they are found in the upper layers
of the epidermis. Sweet syndrome is also referred to as acute
febrile neutrophilic dermatosis. It is a condition of unknown etiology
characterized by pyrexia, elevated neutrophil count, painful
erythematous cutaneous lesions, and usually prompt clinical
improvement is seen following corticosteroid systemic therapy.
The standard therapy for Sweet's syndrome is prednisone or
prednisolone at an initial dose of 0.5 mg/kg to 1.5 mg/kg of body
weight per day, and gradual reduction is recommended for the
following 2 to 4 weeks. Sweet's syndrome can be associated with
other conditions such as Acute Myeloid Leukemia (AML).
The tendency of Sweet's syndrome to relapse was the rationale
for trying cyclosporine as a first-line treatment. Several cases
have been reported demonstrating the efficacy of cyclosporine
for the treatment of Sweet's syndrome.66-70
Cyclosporine had been used in 3 settings: as initial monotherapy,
a second line therapy after the failure of other first-line
treatments (steroids) or as a corticosteroid-sparing agent. The
initial oral dose has ranged from 2 mg/kg/day to 4 mg/kg/day, to
as high as 10 mg/kg/day for the acute presentation; this dose is
continued for the first 10 days and then reduced gradually and
discontinued at day 21. Patients should be closely monitored
due to the side effects.68,69
Cyclosporine has been shown to inhibit neutrophil chemotaxis and,
more importantly, impair neutrophil migration into infective and sterile
inflammatory foci in vivo. Monocyte functions are also modulated
by cyclosporine and it has been shown in vitro to inhibit antigen presentation
and suppress monocyte activation. Even though, Sweet's
syndrome is predominantly a neutrophilic, inhibition of cytokine release
by mature T-helper lymphocyte and decrease of effector found
in cytotoxic lymphocytes has been reported. The mode of acting of
cyclosporine in this disease may be related to these effects.66,69,70
Furthermore, it has been suggested that interleukin 1 (IL-1) might
play a key role in Sweet's syndrome. IL-1 possesses endogenous
pyrogen activity, is chemotactic to neutrophils, induces neutrophil
leucocytosis and stimulates synthesis of prostaglandin E2.
Cyclosporine has been shown inhibit the release of Il-1.70
Cutaneous Lupus Erythematosus
Cutaneous lupus erythematosus includes wide variety of skin lesions. Discoid lupus erythematosus are erythematous, scaly papules and plaques on sun-exposed areas that can leave scarring; of these, fewer 10% will develop systemic disease. Systemic lupus erythematosus can produce malar erythema and widespread maculopapular lesions on the skin. Between these 2 entities, there is a wide spectrum of cutaneous manifestations: annular, psoriasiform (subacute lupus erythematosus), poikiloderma-like, lichenoid, panniculitis, verrucous, or bullous skin lesions.71-73
Cutaneous lupus erythematosus includes wide variety of skin lesions. Discoid lupus erythematosus are erythematous, scaly papules and plaques on sun-exposed areas that can leave scarring; of these, fewer 10% will develop systemic disease. Systemic lupus erythematosus can produce malar erythema and widespread maculopapular lesions on the skin. Between these 2 entities, there is a wide spectrum of cutaneous manifestations: annular, psoriasiform (subacute lupus erythematosus), poikiloderma-like, lichenoid, panniculitis, verrucous, or bullous skin lesions.71-73
Cyclosporine has been used for concomitant treatment of
systemic lupus erythematosus or as a third line therapy for cutaneous
disease. In these settings cyclosporine is given after
antimalarials, dapsone, oral prednisone, and/or retinoids have
failed.71 The recommended dose is between 2.5 mg/kg/day and
5 mg/kg/day, usually starting at a dose of 4 mg/kg/day to 5 mg/
kg/day, and as the patient responds the dose can be decreased.71
In a clinical trial of 59 patients with systemic lupus erythematosus
where other immunosuppressants failed, 75% improved
when treated with cyclosporine, which included skin lesions,
and patients were able to maintain the treatment for 2 years.
Cyclosporine also improved lupus nephritis; thus there is no
evidence of worsening the lupus associated renal disease. In
some patients, however, it elevated the blood pressure; this is
the most frequent reason for discontinuation of the therapy.74
In some cases, a combination of cyclosporine and other immunosuppressant
drugs can allow a reduction in the dose of both
medications, for example, the combination of cyclosporine and
corticosteroids as a steroid-sparing agent73; cyclosporine and methotrexate
have also been reported to be useful and safe,75 though
most of the reports are case series, and further controlled studies
are needed.
Cyclosporine is also useful when lupus is associated with another
inflammatory skin disease, such as lichen planus76 or psoriasis.77
Although these diseases have different clinical and histopathological
features, cyclosporine has proven to be a beneficial treatment
in many of them. Thus, cyclosporine can be used to treat refractory
cutaneous lupus with or without systemic involvement. The recommended
doses are between 2.5 mg/kg/day and 5 mg/kg/day and can
be maintained for 2 years. Also, the combination with corticosteroids
and other immunosuppressant drugs have proven to be beneficial.
Dermatomyositis
Dermatomyositis is an autoimmune disease of the skin and muscles. Skin lesions involve Gottron's papules, heliotrope rash, periungal telangiectasias, and/or facial erythema and edema.78,79 The disease is usually associated with muscle weakness and elevated skeletal muscle enzymes. However, dermatomyositis sine myositis (or amyopathic, ie, without muscle involvement and with the characteristic skin lesions) is well recognized.80 Prognosis is dependent upon the development of internal malignancy, interstitial lung disease, or clinical muscle weakness, which can be profound.
Dermatomyositis is an autoimmune disease of the skin and muscles. Skin lesions involve Gottron's papules, heliotrope rash, periungal telangiectasias, and/or facial erythema and edema.78,79 The disease is usually associated with muscle weakness and elevated skeletal muscle enzymes. However, dermatomyositis sine myositis (or amyopathic, ie, without muscle involvement and with the characteristic skin lesions) is well recognized.80 Prognosis is dependent upon the development of internal malignancy, interstitial lung disease, or clinical muscle weakness, which can be profound.
Cyclosporine is used to treat dermatomyositis as a steroid-sparing
agent; the first-line therapy is glucocorticosteroids in high
doses (1 mg to 2 mg/kg/day), usually associated with another immunosuppressant
treatment like methotrexate or azathioprine.
Cyclosporine can be and has been used as a second-line therapy,
81-83 and for refractory dermatomyositis unresponsive to
methotrexate and azathioprine treatment. In a clinical trial com-